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Background: Phenylketonuria (PKU) is a chronic inborn error of amino acid metabolism that requires lifelong
follow-up and intervention, which may represent strains on Quality of Life (QoL). This observational study evaluated
QoL in a cohort of PKU patients, using updated and detailed instruments.
Methods: 22 patients with mild PKU respondent to BH4 and 21 patients with classical PKU treated with diet were
recruited in this study. Adult patients completed WHOQOL questionnaire-100 (WHOQOL-100) and pediatric patients
the Pediatric QoL inventory (PedsQLTM). Psychiatric and mood disorders were also evaluated using TAD or BDI and
STAI-Y inventories. A multivariable linear regression model was fitted to investigate the predictors of QoL, including
age, sex, treatment type, length of current treatment, educational level and employment status (only for adults) as
covariates. Results were presented as regression coefficients with 95% confidence interval.
Results: Global QoL scores were within normal range both in patients with mild and classical disease but global
QoL scores were significantly higher in patients with mild PKU under BH4 treatment as compared to those affected
by classical disease who were under diet regimen. Furthermore, QoL significantly increased in long treated PKU
patients. Among adult patients, QoL scores were significantly lower in males, in patients with lower education and
in those employed or unemployed as compared to students (baseline).
Conclusions: Both diet and medical treatment based upon BH4 seem to be associated with higher QoL in the long
run. However, patients with mild PKU can rely on BH4 to achieve a higher Phe tolerance and a better compliance
to therapy due to diet relaxation/avoidance. Some specific categories of patients with a lower QoL should be
investigated more in depth, engaging with those at risk of lower treatment compliance. The questionnaires
employed in the present study seemed to be able to effectively detect criticalities in QoL assessment and represent
an advance from previous inventories employed in the past.
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questionnaire-100Background
Phenylketonuria (PKU, OMIM 261600) is a complex auto-
somal recessive metabolic disorder caused by mutations of
the gene encoding for phenylalanine hydroxylase enzyme
(PAH, EC 1.14.16.1). PAH deficiency leads to an accu-
mulation of phenylalanine (Phe) in blood and brain that
gradually impairs metabolic functioning and cognitive de-
velopment [1]. PAH is mainly active in the liver and* Correspondence: alberto.burlina@unipd.it
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unless otherwise stated.requires 6R-tetrahydrobiopterin (BH4) as a critical cofac-
tor. An early dietary intervention based on a Phe restricted
diet and the supplementation of an amino acids mixture is
able to keep Phe blood levels low, avoiding mental re-
tardation or neurological abnormalities that have been
described in untreated patients [2]. Diet should be main-
tained lifelong and this requires a lot of effort, especially in
adulthood, owing to the growing instances of social rela-
tionships [3-5]. Indeed, PKU patients must go through fre-
quent biochemical controls, several dietary assessments
and adjustments that represent stressors for both ado-
lescent and adult patients [6,7]. Furthermore, in youngl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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culties in building up good social relationships [8], often
resulting in poor adherence to dietary regimen with risks
of cognitive, neuropsychological and behavioural impair-
ment [9,10]. BH4 has been introduced since 1999 as a
therapeutic option alternative to diet to manage PKU, thus
widely changing the matter [7,11]. In PKU responsive pa-
tients, BH4 indeed allows to maintain a significantly low
level of blood Phe, despite remarkable relaxation of dietary
regimen [12,13]. Current guidelines suggest that a trial
with sapropterin can be provided to all PKU patients [13],
nevertheless patients with milder forms of the disease are
more likely to benefit from BH4 treatment than classical
ones.
In recent years there has been increasing attention on
the effect of BH4 on the Quality of Life (QoL) of PKU
patients previously receiving dietary intervention [14-16].
However QoL scores of PKU patients and their parents
measured by current inventories are reported to be gener-
ally similar to healthy controls’ [14,17,18], probably as the
questionnaires are not able to outline differences or critic-
alities expected in a chronic disease. Demirdas et al. and
Ziesch et al. [14,16], for instance, investigated QoL of PKU
patients using several instruments, before and after the
introduction of BH4 [19]. Their results showed that:
a) QoL global scores were comparable to the ones of
general population;
b) QoL scores did not improve after BH4
administration and consequential relaxation of diet.
The authors attributed their findings to several reasons:
– global QoL scores reflect a true picture;
– results are the consequence of a hidden disability
hard to capture;
– QoL instruments are not enough sensitive to detect
differences;
– sample of patients is underpowered;
– period of treatment is too short to reveal long term
changes.
Therefore more appropriate instruments to evaluate
QoL of PKU patients seems to be required.
WHOQOL-100 [20] and PedsQL are two question-
naires recently devised to better evaluate QoL as com-
pared to previous instruments.
In view of the above, the present study aimed to
assess WHOQOL-100 and PedsQL questionnaires to
score personal and parental perception of QoL in a
sample of PKU patients affected by mild and classical
PKU. Indeed, QoL of patients with mild and classical PKU
have never been compared using up-to-date instruments
thus far.Methods
Study planning and sample portrayal
This study was conducted from March 2012 till July
2012, as a result of the collaboration of Padua University
Hospital (enrolling pediatric patients) with the Neuro-
logical Unit of St. Bassiano Hospital in Bassano del
Grappa (enrolling adult patients). The study protocol
followed the principles of the Declaration of Helsinki
and ICH/GCP and was approved by the Ethical committee
of the Padua University Hospital. All recruited patients
and/or their respective parents signed an informed
consent.
A total of 30 mild BH4 potentially respondent pa-
tients have been selected to participate to the study. 3
of them were excluded due to age criteria (patients
under 4 years of age), 2 were excluded due to the pres-
ence of mental impairment and 3 did not give their
consent to participate to the study. An almost identical
number of classical PKU patients were then recruited
considering gender, disease severity and age-matching
criteria.
Thus 22 BH4 responsive patients affected by mild PKU
and 21 classical PKU patients treated with diet were re-
cruited in this study. Information on age (in years), gen-
der, treatment type (BH4 vs. diet), treatment length
(months of current treatment, diet or BH4 therapy), em-
ployment status of adult patients (student, employed,
unemployed) and educational level of pediatric (nursery,
primary school, junior secondary school) or adult pa-
tients (secondary school or post-graduate education)
were collected.
Patients affected by mild PKU treated with BH4 were
included if:
– PKU was diagnosed by neonatal screening;
– Phe blood level ranged between 600 and 1200 μmol/L;
– a significant decrease of blood Phe level (>30%)
following a BH4 loading test (performed with a BH4
dosage of 20 mg/kg/day).
Genetic analysis was conducted in all patients (both in
mild PKU patients treated with BH4 as well as in classical
PKU patients on diet). All patients with mild PKU were,
thereafter, treated with a BH4 dosage of 10 mg/Kg/day, as
suggested by Kure et al. [11], for a time period of 1 to
11 years. Until 2009 BH4 was provided by Schircks La-
boratories in Switzerland; subsequently there was a
switch to sapropterin dihydrochloride (Kuvan®, Merck
Serono, Germany). All patients on BH4/sapropterin
treatment were allowed a relevant relaxation of the diet-
ary restriction [21].
Analysis of Phe was performed using liquid chroma-
tography/tandem mass spectrometry (CC-MS/MS) as
previously described [22].
Cazzorla et al. BMC Public Health 2014, 14:1243 Page 3 of 9
http://www.biomedcentral.com/1471-2458/14/1243Technical instruments and questionnaires
A general instrument for QoL perception was adminis-
tered to all study subjects.
In detail, for pediatric patients (6-16 years old) the
Pediatric Quality of Life Inventory, PedsQL, was employed,
an instrument measuring several aspects of QoL including
a child self-report and a parent proxy-report format [23].
PedsQL consists of Likert scale items and yields a score
scale for Physical Functioning, Emotional Functioning,
School Functioning and Social Functioning. Items are
reverse-scored and linearly transformed in a 0-100 scale,
with higher scores corresponding to higher QoL. The
PedsQL was self-administered for children 8-16 years old
and by parents and administered by an interviewer to chil-
dren 6-7 years old. In order to analyse the participants’
scores (children and their respective parents), results were
compared with age-matched normative data controls
taken from literature [24]. The Test of Anxiety and De-
pression in Infancy and Adolescence, TAD, was also used,
an inventory including a self and a proxy-report [25]. This
instrument enables to investigate the symptoms associated
with anxiety and depression.
For adult patients (18-35 years old) the World Health
Organization QoL score (WHOQOL-100) was employed,
recording the global perception of their own QoL [20].
Items are linearly transformed into a 4-20 scale, with
higher scores corresponding to higher QoL. This instru-
ment was previously used also to test QoL in patients with
other inherited metabolic diseases [8]. Age-matched nor-
mative data (age range: 18-44 years) taken from literature
[26] was considered in the analysis.
The Beck Depression Inventory, BDI, a self-report in-
strument, which is both clinical and diagnostic, was also
used to evaluate the presence and the degree of depres-
sion [27]. In this instrument the total score is compared
to a reference value, to determine the severity of depres-
sion. Higher total scores are associated with more severe
depressive symptoms.
Finally, the State-Trait Anxiety Inventory form Y
(STAI-Y) was employed, an instrument which investi-
gates the level of anxiety in adult patients. This inven-
tory discriminate between state anxiety, for instance a
transitory emotional condition, from trait anxiety, de-
fined as a personality trait [28].
Statistical analysis
The ANOVA test was employed to compare the mean
values of Phe of BH4 patients and patients on diet. Four
univariable linear regression models were employed to
assess the association between QoL and Phe levels at as-
sessment day and over the past 12 months in both
groups (mild PKU on BH4 treatment and classical pa-
tients on diet). Two separate multivariable linear regres-
sion models were set up to investigate the effect ofvarious predictors on QoL (as continuous outcome) per-
ceived by the patients. The first model was fitted only on
pediatric PKU patients controlling for age, sex, treatment
type (BH4 vs. diet), length of current treatment (diet or
BH4) and educational level. The second model was fitted
only on adults PKU patients, controlling for age, sex, treat-
ment type (BH4 vs. diet), length of current treatment (diet
or BH4), educational level and employment status. Results
of all above models were expressed as regression coeffi-
cients (RC) with 95% confidence interval (95% CI).
The analysis was conducted with Stata 13 statistical
package (Stata Corporation, College Station, Texas, USA).
Results
Patient sample
Table 1 shows the distribution of the 43 PKU patients
(20 females and 23 males) aged between 6 and 35 (mean
17.1 ± 9.0): 22 BH4 responsive patients (aged between 6
and 35 years; mean = 15.4 ± 9.5) affected by mild PKU,
and 21 classical PKU patients treated with diet (aged be-
tween 8 and 34 years; mean = 18.9 ± 8.3).
Patients were broken down as follows:
– a group of 26 pediatric patients aged between 6 and
16 years with their respective parents;
– a second group of 17 adult patients aged between 17
and 35 years.
Three pediatric patients (11.5%) were attending nur-
sery, twelve (46.2%) attended primary school and eleven
(42.3%) attended junior secondary school. Fourteen
adults patients (82.4%) had a secondary school education
and three (17.6%) had a post-graduate education. Five
adult patients (29.4%) were students, nine (52.9%) were
employed and three (17.7%) were unemployed.
The average length of current treatment (diet or BH4)
was 209.65 ± 140.02 months. The mean QoL of pediatric
patients was 79.26 ± 82.97, whereas in adults it was
16.47 ± 0.51.
Tables 2 and 3 presents the biochemical, therapeutic
and personal data of all patients:
– 21 classical PKU patients treated with diet alone;
– 6 adult patients treated with sapropterin alone;
– 8 patients (all pediatric patients) treated with
sapropterin as well as low protein foods and natural
proteins (mainly from animal sources);
– 8 patients (7 children and 1 adult) requiring a
combined treatment of sapropterin along with Phe
restricted diet and a supplementation of Phe-free
amino acid compounds.
BH4 was generally well tolerated and no adverse events
were reported over the years.
Table 1 Frequency distribution of the 43 PKU patients
Variables Strata No. (%) Mean ± SD Mean ± SD normative
population (Child Self-report)
Mean ± SD normative population
(Parent proxy-report)
Gender Female 20 (46.5)
Male 23 (53.5)
Age (years) 17.09 ± 8.98


















Treatment type Diet 21 (48.8)
BH4 22 (51.2)
Treatment length (months) 209.65 ± 140.02
QoL pediatric (range: 0-100) 79.26 ± 82.97 79,37 ± 10 [24] 81,74 ± 11,21 [24]
QoL adults (range: 4-20) 16.47 ± 0.51 14,9 ± 2,9 [26]
Number (No.), percentage (%), mean and standard deviation (SD).
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sponsive variants [15,19,29-35] of PAH gene and previ-
ously known classical PKU variants [36].
Blood Phe levels
Blood Phe concentrations of all patients on BH4 treatment
were within the therapeutic range both on the day of as-
sessment and over the course of previous 12 months, in
compliance with the Italian guidelines (0-12 years range:
120-360 μmol/L; >13 years range: 120-600 μmol/L) [13].
Phe tolerance increased 2-4 times above normal values
following BH4 treatment [21].
Tables 2 and 3 shows that the mean blood Phe con-
centration in pediatric patients on diet regimen fell
within the borderline range both on the day of assess-
ment (mean = 357 ± 150 μmol/L) and over the course of
previous 12 months (mean = 359 ± 131 μmol/L).
The mean blood Phe concentration in adult patients
on diet regimen was above the recommended upper
limit both on the day of assessment (mean = 826 ±
261 μmol/L) and over the course of previous 12 months
(mean = 777 ± 240 μmol/L).
The mean Phe levels of mild PKU patients on BH4
were significantly lower than classical PKU patients on
diet (Table 4).
Finally, QoL of both groups (mild PKU patients on
BH4 and classical PKU patients on diet) was significantlycorrelated with the average value of Phe over the previ-
ous 12 months and Phe value measured on the day of
assessment (see Table 5).
Quality of life
Parents’ perception of patients QoL showed no significant
mean differences as compared to normative children’s data.
Moreover, patients’ perception of QoL did not significantly
differ from normative data. There was no statistically signifi-
cant correlation between parents and children perception of
QoL. The trend tended towards 0 in every instrument
observed (Correlation Coefficient = 0.148, p > 0.05).
As it can be seen from Table 6, after holding constant the
effects of all other predictors, mean QoL score in pediatric
patients was significantly higher in pediatric patients with
mild PKU on BH4 treatment (RC = 15.12; 95% CI: 3.08;
27.15) as compared to pediatric patients affected by
classical disease treated with diet (reference). A significantly
increase of QoL (RC = 0.11; 95% CI: 0.01;0.21) was also
observed in long treated patients (either diet or BH4).
Similar results were also observed for adult patients
(Table 7). By holding constant the effect of other terms,
mean QoL scores were indeed significantly higher in
adult patients with mild PKU under BH4 treatment (RC =
7.89; 95% CI: 2.47; 13.31) as compared to patients with
classical PKU on diet (reference). In adult patients QoL
was also significantly lower in males (RC = -2.58; 95% CI:










over the course of
the previous 12 months
I 6 F 313 292
II 10 M 416 361
III 8 F 358 350
IV 8 F 326 250
V 10 M 373 254
VI 10 F 664 553
VII 7 M 268 261
VIII 16 F 189 256
IX 6 M 254 335
X 10 F 222 224
XI 6 M 142 166
XII 11 F 240 251
XIII 16 F 309 364
XIV 16 M 251 268





Age Sex Phe valuesa
on the day of
assessment
Mean Phe valuesa
over the course of the
previous 12 months
XVI 15 M 471 318
XVII 8 M 473 343
XVIII 15 F 611 394
IXX 15 M 262 386
XX 8 M 273 291
XXI 10 F 396 320
XXII 13 F 128 476
XXIII 13 F 239 216
XXIV 9 F 288 321
XXV 16 F 563 678
XXVI 12 M 254 206
*10 mg/Kg/day for each patient.
aExpressed in μmol/L.










over the course of the
previous 12 months
I 26 M 273 255
II 35 M 502 541
III 30 M 654 586
IV 32 F 683 646
V 21 F 652 666
VI 18 M 349 414









over the course of the
previous 12 months
VIII 28 F 922 1032
IX 27 F 624 608
X 18 F 635 557
XI 28 M 1359 1238
XII 27 M 917 784
XIII 17 F 481 442
XIV 30 M 1120 950
XV 29 M 735 638
XVI 34 M 782 800
XVII 24 F 682 719
*10 mg/Kg/day for each patient.
aExpressed in μmol/L.
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higher in those with postgraduate education (RC = 3.26;
95%CI: 1.33; 5.18) as compared to patients with secondary
school education (reference). Lastly, adult patients, employed
(RC = - 2.22; 95% CI: -4.26; -0.18) or unemployed
(RC = - 2.73; 95% CI: -4.79; -0.66), had a significantly lower
average QoL scores as compared to students (reference).
TAD, BDI and STAI-Y
TAD, BDI and STAI-Y scores were within normal values
in all patients and none of the estimates reached statistical
significance. In particular at the TAD test:– 2 parents out of 15 reported a mild level of
depression in their children;
– 3 parents out of 15 reported a mild level of anxiety
in their children;
– 2 parents out of 15 reported a mild level of social
difficulties in their children;
– only 1 pediatric patient under BH4 treatment
reported mild level of anxiety.
In the adult population, the BDI did not detect any
pattern of depression whereas the STAI-Y displayed that
two adults on dietary treatment reported anxiety (data
not shown in any table).
Discussion
In the present study QoL was evaluated among 22
patients affected by mild PKU treated with BH4 and
21 patients with classical PKU on diet. Although QoL
global scores were normal in both groups, both
pediatric and adult patients affected by mild PKU
treated with BH4 reported a significantly higher QoL
scores than patients with classical PKU on diet.
Table 4 ANOVA test comparing the mean Phe level of patients with classical PKU on diet and mild PKU on BH4
Mean ± SD RC (95% CI) p value
Classical PKU patients on diet 579.95 ± 315.75 Reference <0.01
Mild PKU patients on BH4 362.09 ± 164.36 -217.86 (-371.85; -63.87)
Mean, standard deviation (SD), 95% confidence interval (95%CI) and p value.
Table 5 Association between Phe levels (in the previous
12 months and at assessment) and QoL scores in mild
PKU patients on BH4 treatment and classical patients on
diet expressed as regression coefficients (RC) with 95%
confidence intervals (95%CI) and p values
Mild PKU patients on BH4
RC 95% CI p value
phenylalanine in previous 12 months - 0.13 (-0.21; -0.05) < 0.01
phenylalanine at assessment - 0,11 (-0.18; -0.04) < 0.01
Classical PKU patients on diet
RC 95% CI p value
phenylalanine in previous 12 months - 0.08 (-0.12; -0.04) < 0.01
phenylalanine at assessment - 0.08 (-0.11; -0.04) < 0.01
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significant increase of QoL was observed in long
treated patients, irrespective if it was diet or BH4
therapy. This finding seems to suggest that both
treatments (diet or BH4) are effective to improve QoL
of PKU patients in the long run. This could be attrib-
utable to increasing compliance to treatment over
time (irrespective of treatment type).
Diet remains the mainstay for patients with classical
disease, whereas those affected by mild PKU and strug-
gling to adhere to diet regimen have the opportunity to
rely on BH4 medical treatment.
Several studies support the effectiveness of BH4 in lower-
ing blood Phe levels. However, there is lack of data for long
term treated patients and the biochemical effect still does
not have a clear counterpart in terms of QoL and behaviour
for PKU patients on diet [15,16], whose QoL scores were
reported to be similar to healthy controls [17,37,38]. Glo-
bally speaking, all previous studies suggested that PKU pa-
tients have QoL scores similar to the healthy populations.
Only Cotugno et al. [39] reported lower parental QoL
scores as compared to non-PKU patients. Gentile
et al. [40] recently stated that this could be due to a
sort of “hidden disability” effect, a cumulative impact
of relatively subtle symptoms not easy to be detected
by currently used QoL questionnaires. Nevertheless,
adolescents and adult patients reported that adherence to
diet is arduous [4-6,41] and diet treatment significantly
limits their daily life activities.
In this study WHOQOL-100 and PedsQL were
employed, two recently developed inventories to assess
global QoL. In particular, WHOQOL-100 was devel-
oped to further improve QoL assessment in comparison
to previous instruments, both by extending the number
of the questions and by enabling cross-cultural compar-
isons. Previous instruments were developed based upon
SF-36, a health related QoL scale encompassing objective
measures in addition to perceived state [42]. Above all, in
the SF-36 instrument physical health subscales refers
largely to physical symptoms (such as pain, mobility, fa-
tigue) and is probably more adequate to investigate QoL
in other medical conditions. In disorders such as PKU,
where physical illness is less severe than daily life limi-
tations, other aspects of QoL may be more relevant to
evaluate. Moreover, WHOQOL-100 has a good dis-
criminatory power in its physical and independence
domains [43] and includes a detailed section, under theindependence domain, focused on the influence of
medication and medical aids in daily life activities.
In this sense, WHOQOL-100 encompasses a larger
number of dimensions (level of independence, per-
sonal relationship, positive feelings, sexual activity
and also dependence on medical substances/aids) that
seems more suitable to better assess PKU treatment
constraints.
However, in the present study parents’ perception of
patients’ QoL showed no significant mean differences as
compared to parents’ of healthy children. Moreover,
patients’ perception of QoL did not significantly differ
from normative data. Even advanced and detailed
QoL instruments, as those employed in the present
study, therefore are still not able to detect some crit-
icalities in the assessment of QoL for PKU patients.
Future inventories should be improved by focusing
more on the perception of personal limitations and
on the social implications associated with a chronic
and restrictive dietary regimen.
Male gender was found to be significantly associated
with lower QoL among adult patients. This evidence
was never reported before in any study and deserves
attention. The latter finding, not confirmed for male
pediatric patients, might be explained by parental
control. In this study adult students had a significantly
higher QoL score than employed and unemployed
patients. The impact of education and socio-economic
status is indeed confirmed by the significantly higher
QoL score found in adult patients with higher education
in this study.
Table 6 Multivariable linear regression model for the
quality of life in the 26 pediatric PKU patients
Variables No (%) RC (95% CI) p value
Gender
Female 12 (46.2) Reference 0.66
Male 14 (53.8) - 1.59 (-8.91; 5.74)
Age (years)
10.81 ± 3.51 - 0.33 (- 2.96; 2.29) 0.79
Education level
Nursery 3 (11.54) Reference 0.80
Primary school 12 (46.15) - 1.79 (- 15.88; 12.31)
Junior secondary school 11 (42.31) 5.96 (-20.07; 31.98)
Treatment
Diet 11 (42.3) Reference 0.02
BH4 15 (57.7) 15.12 (3.08; 27.15)
Length of current
treatment (months)
89.08 ± 61.86 0.11 (0.01; 0.21) 0.03
Number (No.), percentage (%), regression coefficients (RC) with 95% confidence
intervals (95%CI) and p values. Model fitted on 26 complete observations.
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hard to manage PKU both for patients and parents, often
engendering anxiety and fear of not being able to ad-
equately control the course of the disease [18]. Also,
parental mental reaction certainly has an impact onTable 7 Multivariable linear regression model for the
quality of life in the 17 adult patients
Variables No. (%) RC (95% CI) p value
Gender
Female 8 (47.1) Reference 0.01
Male 9 (52.9) -2.58 (-4.44; -0.72)
Age (years)
26.71 ± 5.46 -0.16 (- 0.33; 0.02) 0.08
Education level
Secondary School 14 (82.4) Reference <0.01
Post-graduate 3 (17.6) 3.26 (1.33; 5.18)
Employment status
Student 5 (29.4) Reference 0.01
Employed 9 (52.9) - 2.22 (-4.26; -0.18)
Unemployed 3 (17.7) - 2.73 (-4.79; -0.66)
Treatment
Diet 10 (58.8) Reference 0.01
BH4 7 (41.2) 7.89 (2.47; 13.31)
Length of current
treatment (months)
209.65 ± 140.02 0.03 (0.01; 0.21) 0.01
Number (No.), percentage (%), regression coefficients (RC) with 95% confidence
intervals (95%CI) and p values. Model fitted on 17 complete observations.children’s emotional development [44,45]. In addition,
high levels of stress are related to the burden of treat-
ment management, with a subsequent increased risk of
depression and anxiety [9,46]. Indeed internalizing psy-
chiatric disorders such as anxiety and depression have
been frequently described in association with PKU [46].
In the present study BDI, TAD and STAI-Y were also
administered, questionnaires never previously used to
evaluate PKU patients. In terms of psychiatric symp-
toms, no patients scored for depression. By contrast,
one patient reported mild levels of anxiety.
Several previous studies have focused on behavioural,
psychiatric and social functioning in PKU patients
[9,40,46] with controversial results [47-49]. Although it is
not possible to depict a clear psychological phenotype, in-
ternalizing traits (such as depressed mood, phobias and
anxiety) have been frequently described, mostly in adult
women. The results of this study confirmed that some
PKU patients presented internalizing personality traits
(predominantly anxiety maladaption) hard to define by
currently used psychiatric inventories.
From a biochemical perspective, mild PKU patients on
BH4 treatment showed better metabolic control, with lower
mean blood Phe levels and lower variability towards mean
values (lower SD). When compared with QoL scores, Phe
level was significantly correlated with QoL in both groups, at
assessment as well as over the course of previous 12 months.
Limitations
The results of the present study should be interpreted
with caution.
Although the distribution by gender (21 males vs. 22
females) and disease severity (22 mild vs. 21 classical)
was fairly homogeneous, the age distribution of both
groups (patients with mild PKU on BH4 and patients
with classical PKU on diet) was heterogeneous.
Moreover, better QoL scores might be due to a less se-
vere disease and a better self-assessment. On the other
hand it can be argued that global QoL scores may be
simply lower in patients with classical PKU as compared
to those affected by mild disease, due to the burden of
diet. In the present study mild PKU patients on BH4 in-
deed slightly differed from classical ones on diet as the
former were affected by milder disease.
Despite a relatively small sample size, this work pro-
vided significant results which might contribute to assess
and improve currently used inventories for the detection
of QoL in PKU patients. Some statistical estimates may
become significant with a larger study. Probably a multi-
center study would be required to enlarge the cohort
and reach stronger statistical power.
Finally, since the results come from a cross sectional
study, a stronger study design is recommended to con-
firm the above findings.
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The aim of the present study was to investigate various
aspects of QoL in a group of patients affected by mild
and classical PKU, in relation to different treatment regi-
men (BH4 vs. diet). Global QoL scores were found to be
significantly higher in patients with mild PKU treated
with BH4 as compared to patients with classical disease
on dietary treatment, both in the adult and the pediatric
group. Some specific categories of adult patients (males,
those less educated and non students) reported a signifi-
cantly lower QoL score and should be investigated more
in depth, targeting categories patients with potential low
treatment compliance. Finally, this study confirmed that
currently used QoL inventories constitute a significant
advance from instruments employed in the past; how-
ever further improvements of these inventories are still
recommended.
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